Phytopharm plc Stock London S.E.
Stocks
GB0006869720
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 07-13 | Oil rises as Iran escalation keeps FTSE subdued | AN |
| 07-13 | Ixico notes ending of Huntington's disease programmes | AN |
| Market Cap | 17.99M 24.25M 21.2M 19.6M 34.05M 2.34B 34.64M 234M 91.84M 1.14B 91.07M 89.07M 3.94B | P/E 2026 * |
-5.89x | P/E 2027 * | -6.35x |
|---|---|---|---|---|---|
| Enterprise Value | 7.79M 10.5M 9.18M 8.49M 14.74M 1.01B 15M 101M 39.77M 494M 39.43M 38.57M 1.71B | EV / Sales 2026 * |
0.97x | EV / Sales 2027 * | 1.32x |
| Free-Float |
89.25% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Phytopharm plc
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 53 | 2024-08-18 |
Grant Nash
DFI | Director of Finance/CFO | 50 | 2019-08-20 |
Mark Austin
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 51 | - |
Grant Nash
BRD | Director/Board Member | 50 | 2019-08-20 |
Katherine Rogers
BRD | Director/Board Member | 60 | 2022-01-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.07% | +0.38% | +2.06% | +5.66% | 50.35B | |
| -2.85% | -6.25% | +366.61% | +573.36% | 39.21B | |
| +1.78% | +0.73% | +32.68% | -4.91% | 34.52B | |
| +1.98% | +4.82% | +13.71% | +60.39% | 34.6B | |
| +0.06% | -0.57% | +3.35% | +27.42% | 27.05B | |
| -3.27% | -5.67% | - | - | 16.68B | |
| +1.64% | +0.45% | +70.86% | +117.46% | 15.11B | |
| +0.29% | +3.64% | +15.30% | +17.80% | 13.85B | |
| -1.21% | +0.73% | +18.02% | -30.62% | 13.18B | |
| Average | -0.39% | +0.81% | +65.32% | +95.82% | 27.17B | |
| Weighted average by Cap. | -0.46% | +0.70% | +77.64% | +118.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8M 10.78M 9.43M 8.72M 15.14M 1.04B 15.4M 104M 40.84M 507M 40.5M 39.61M 1.75B | 9M 12.13M 10.61M 9.81M 17.03M 1.17B 17.33M 117M 45.95M 571M 45.56M 44.56M 1.97B |
| Net income | -2.14M -2.89M -2.53M -2.34M -4.06M -278M -4.13M -27.85M -10.94M -136M -10.85M -10.61M -469M | -2.8M -3.78M -3.3M -3.05M -5.3M -364M -5.39M -36.4M -14.3M -178M -14.18M -13.87M -613M |
| Net Debt | -10.2M -13.75M -12.02M -11.12M -19.3M -1.33B -19.64M -133M -52.08M -647M -51.64M -50.5M -2.23B | -6.1M -8.22M -7.19M -6.65M -11.55M -792M -11.75M -79.28M -31.14M -387M -30.88M -30.2M -1.34B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
